ResearchResearch summary
Vaginal yeast infection: 2026 management review
A narrative review discusses diagnosis and management of vaginal yeast infection, but reports no pooled results or direct maintenance-route comparison.
In this pathway
- Current topic
- Vaginal yeast infection: 2026 management reviewCurrent
Bottom line
This state-of-the-art review brings together background on vaginal yeast infection and recurrent vulvovaginal candidiasis. It reports no new treatment cohort, pooled absolute estimate, or direct oral-versus-topical maintenance comparison.
Why this source matters
The review provides broad context on diagnosis and management, with an emphasis on recurrent VVC. Its narrative approach makes it useful alongside the more direct studies and guidance that anchor treatment conclusions.
Study and population
This is a state-of-the-art narrative review, not a systematic review or clinical study. It cites 101 references and defines no participant population of its own; no treatment cohort was recruited.
What was examined
The authors discuss published work on VVC and recurrent VVC, including diagnosis and management. The review assigns no treatment, enrolls no comparator group, and conducts no new head-to-head treatment comparison.
Results
The review gives no pooled absolute treatment results. Citing Ventolini (2006), it states that symptoms recur in 50% of patients who stop suppressive treatment. The review provides no numerator, denominator, confidence interval, or time point for this figure; it is an attributed statement from cited literature, not an estimate generated by this review.
Applicability
This source offers a broad overview of published and expert discussion about VVC and recurrent VVC. It does not define one population for the review as a whole, establish a direct maintenance-route ranking, or validate current product access and care actions for a specific country.
Limitations
The review reports no search strategy, search dates, eligibility rules, screening process, risk-of-bias assessment, or quantitative synthesis. Its treatment discussion often lacks denominators and absolute results. The cited 50% post-suppression recurrence statement has no numerator, denominator, confidence interval, or time point in this review.
Contribution to the evidence
This review is contextual. It brings together a wide range of VVC topics but does not replace more direct reviews, trials, guidelines, or the larger body-of-evidence assessment.
Practical change
No practical change. The review does not provide a new pooled estimate or direct oral-versus-topical maintenance comparison, so the evidence map's current conclusions and actions remain in place.
Funding and conflicts
The authors report support from the Medical Research Council Centre for Medical Mycology at the University of Exeter (MR/N006364/2 and MR/V033417/1), NIHR Exeter Biomedical Research Centre (NIHR203320), and NIHR Manchester Biomedical Research Centre (NIHR203308). They state that the views are the authors' and not necessarily those of NIHR or the UK Department of Health and Social Care. The authors reported no conflicts of interest and submitted ICMJE disclosure forms.
Source
Read the original publication (PubMed publication date: 17 March 2026; the issue PDF footer reads 15 March).
Study type, population, and sample scale
- Study type
- State-of-the-art narrative review
- Population
- Published literature on vulvovaginal and recurrent vulvovaginal candidiasis; the review defines no single participant population.
- Sample scale
- No new treatment cohort or pooled participant sample; the narrative review cites 101 references.
Results
- The review reports no new treatment cohort, pooled absolute treatment estimate, or direct oral-versus-topical maintenance comparison.
- Citing Ventolini (2006), the review states that symptoms recur in 50% of patients who stop suppressive treatment. It gives no numerator, denominator, confidence interval, or time point for this figure; it is not a result newly estimated or pooled by the review.
Limitations
- The review describes its scope and cites 101 references.
- It reports no database search, dates, eligibility criteria, screening process, risk-of-bias appraisal, or quantitative synthesis method, so completeness and selection bias cannot be assessed.
- Treatment and newer-agent statements summarize cited studies.
- The review often gives no arm denominators, absolute event rates, effect estimates, or confidence intervals; these statements do not create pooled or comparative estimates.
- The review says symptoms recur in 50% after suppressive treatment stops, citing Ventolini (2006).
- Its text provides no numerator, denominator, confidence interval, or time point for the figure, which is not a new estimate from this review.
Applies to
- A broad overview of published evidence and expert discussion on vulvovaginal candidiasis and recurrent VVC.
- Context on the topics and kinds of treatment literature discussed in this state-of-the-art review.
Does not apply to
- A single treatment population, pooled treatment effect, or direct ranking of oral and topical maintenance.
- Individual treatment selection or current product availability, contraindications, and care routes in a particular country.
Contribution to the current conclusion
Contextual
The broad narrative synthesis adds context on diagnosis and management, especially recurrent VVC, but reports no systematic search methods, pooled treatment estimates, or direct maintenance-route comparison. More direct reviews and current guidance continue to anchor the evidence map.
Related evidence mapPractical change or no change
No practical change. The review adds broad context but does not alter the evidence map's conclusions, establish a maintenance-route ranking, or replace current guidance and locale-specific authority sources.
Funding and conflicts
- Funding
- The authors report support from the Medical Research Council Centre for Medical Mycology at the University of Exeter (MR/N006364/2 and MR/V033417/1), NIHR Exeter Biomedical Research Centre (NIHR203320), and NIHR Manchester Biomedical Research Centre (NIHR203308). They state that the views are the authors' and not necessarily those of NIHR or the UK Department of Health and Social Care.
- Conflicts
- The authors reported no conflicts of interest; all authors submitted ICMJE disclosure forms.
- Paper date
- 2026-03-17
Sources
View all 1 source
- State-of-the-Art Review: Managing Vulvovaginal Candidiasis
- Source type
- Other
- Published
- 2026-03-17